David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience and Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC, Assumes Chief Development Officer Role
Chemomab Therapeutics, Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that David M. Weiner, MD, has been named Interim Chief Medical Officer and Jack Lawler, Senior Vice President of Global Medical Operations at Chemomab, has been named Chief Development Officer. Dr. Weiner, who is based in the U.S., was Interim Chief Medical Officer (CMO) at Chemomab in 2021-2022 and has served as a consultant to the company in the years since. He has more than 25 years of experience in the discovery and clinical development of novel therapeutics and has held senior executive roles at private and public biotechnology companies. Dr. Weiner is replacing Matt Frankel, MD. Mr. Lawler joined Chemomab in 2022 and is also based in the U.S. He has 25 years of clinical drug development experience, including contributing to the development of eight approved pharmaceutical products across a variety of therapeutic indications.
Health Technology Insights: CEUS Offers Safe, Useful Diagnostic Imaging Option for Pregnant Women
“We are delighted that Dave Weiner is rejoining the company,” said Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab. “Dave has worked with Chemomab for a number of years and was a major contributor to the design of the clinical program that resulted in the successful nebokitug Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). We anticipate a smooth transition with our PSC Phase 2 program now successfully completed and our planning for next steps underway. We also want to thank Matt Frankel for his contributions to our medical and clinical achievements and we wish him success in his future endeavors.”
Dr. Mor continued, “Jack Lawler has been instrumental in our clinical progress over the past three years. His leadership in building a first-rate U.S.-based clinical organization that successfully implemented a global PSC clinical program for nebokitug and delivered positive clinical results on budget and ahead of schedule has been invaluable. Jack also helped spearhead our efforts to build strong relationships with PSC opinion leaders, leading clinical centers and advocates worldwide that will serve us well going forward.”
Health Technology Insights: Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for our industry but with our experienced team and record of cost-effective scientific and clinical progress, I am optimistic we will realize the great medical, clinical and commercial potential of nebokitug. I look forward to working again with Jack, who I view as among the most effective clinical operations experts in our industry.”
David Weiner has 30 years’ experience in the discovery and development of novel therapeutics. He is currently Chief Scientific Officer and a director at AxoSIm, Inc. and a director at Bright Minds Biosciences and Novoron Bioscience. Previously he served in multiple leadership roles in neurology and rare disease-focused biotechnology companies, including as Interim Chief Medical Officer at Chemomab Therapeutics, as Chief Executive Officer of Amathus Therapeutics and as Chief Medical Officer at Lumos Pharma, aTyr Pharma and Proteostasis Therapeutics. Earlier in his career, Dr. Weiner held key drug development roles at EMD/Merck Serono and spent a decade in discovery research and clinical development at Acadia Pharmaceuticals. Dr. Weiner received a BA degree cum laude with highest honors from Brandeis University and an MD degree from the School of Medicine and Biomedical Sciences, SUNY Buffalo. He did a post-doctoral fellowship in neuropharmacology at the University of Vermont and was a Howard Hughes Medical Institute Research Scholar. Dr. Weiner has co-authored over 30 scientific publications and multiple patents. He serves as a director, consultant and scientific and clinical advisory board member to biotechnology companies and foundations, including the Michael J. Fox Foundation for Parkinson’s Research.
Prior to joining Chemomab, Jack Lawler served on the senior leadership team at Goldfinch Bio as Vice President, Clinical Operations and Data Management. Earlier, Mr. Lawler held a series of drug development positions of increasing responsibility at biopharmaceutical firms including Cephalon (acquired by Teva), Trevena, Viropharma (acquired by Shire), Botanix and Egalet. He participated in the successful development of numerous pharmaceutical products, including Cinqair, Provigil and Nuvigil, among others. Earlier in his career, Mr. Lawler worked in emergency and transplant medicine. He earned a Bachelor of Science degree summa cum laude from Rosemont College.
Health Technology Insights: PRISM BioLab and Elix Partner to Accelerate AI-Driven Drug Discovery
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobalNewswire
